Other
CDK4/6 Inhibitor
0
Pipeline Programs↗
5
Active Trials↗
2
Companies Involved↗
CDK4/6 Inhibitor is an early-stage landscape with 0 programs across 2 companies. The most active players are G1 Therapeutics, Inc., AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
8
clinical trials
Active, not recruiting3 · 38%
Unknown status2 · 25%
Completed1 · 13%
Enrolling by invitation1 · 13%
Recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Recruiting·—·Phase 2·NCT03310879·38 enrolled
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Active, not recruiting·—·Phase 2·NCT04010357·14 enrolled
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
Enrolling by invitation·—·Phase 2·NCT06481956·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)